Deccan Fine Chemicals Private Ltd has announced the acquisition of Escientia Switzerland AG. In future, it will be called Primopus. Escientia, the Swiss subsidiary of the U.S. company Escientia Life Sciences Group, was established in 2020 with the support of Standortförderung Baselland and the location and innovation promotion agency Basel Area Business & Innovation.
According to a press release, Deccan, one of the world’s largest contract development and manufacturing organizations (CDMO), will be investing in a production plant taken over from Novartis spanning 17,000 square meters as part of this acquisition. It is expected to become operational in the second half of 2023.
According to the information provided, Primopus will focus on providing a hybrid supply chain for the pharmaceutical industry from its location in the canton of Basel-Landschaft. This will be linked to Deccan’s three large fine chemical sites in India. Furthermore, Deccan has announced that Primopus will further develop its research and development capacities.
Marcel Velterop has been named as the CEO. He commented that he is certain that bridging the skills and capabilities of the Swiss operation with the large talent and capacity pool in India will bring unique value and assurance to global players in the pharma supply chain, especially in the current geopolitical environment.
